Prevalence and specificity of the abnormal niacin response: A potential endophenotype marker in schizophrenia

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 369-376

  Yao, Jeffrey K ^a,b,c   Dougherty, George G ^a,b   Gautier, Clara H ^a   Haas, Gretchen L ^a,b   Condray, Ruth ^a   Kasckow, John W ^a,b   Kisslinger, Benjamin L ^a   Gurklis, John A ^a   Messamore, Erik ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bipolar disorder; EC50; Laser doppler flowmeter; Maximal blood flow; Niacin induced flush response; Phospholipid Arachidonate eicosanoid signaling

Indexed keywords

NICOTINIC ACID; NICOTINIC ACID METHYL ESTER; VASODILATOR AGENT;

AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; BLOOD FLOW; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOPPLER FLOWMETER; EARLY DIAGNOSIS; EC50; ENDOPHENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAXIMAL BLOOD FLOW; NIACIN RESPONSE ABNORMALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; ADULT; FEMALE; FLUSHING; LASER DOPPLER FLOWMETRY; MALE; METABOLISM; MIDDLE AGED; PREVALENCE; PSYCHOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; BIPOLAR DISORDER; ENDOPHENOTYPES; FEMALE; FLUSHING; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; NIACIN; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; VASODILATOR AGENTS;

EID: 84964913804     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv130     Document Type: Article

References (36)

1. Liu CM, Chang SS, Liao SC, et al. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res. 2007;152:181-187.
2. Messamore E, Hoffman WF, Janowsky A. The niacin skin flush abnormality in schizophrenia: A quantitative doseresponse study. Schizophr Res. 2003;62:251-258.
3. Smesny S, Berger G, Rosburg T, et al. Potential use of the topical niacin skin test in early psychosis - A combined approach using optical reflection spectroscopy and a descriptive rating scale. J Psychiatr Res. 2003;37:237-247.
4. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005;115:3400-3403.
5. Zellner C, Pullinger CR, Aouizerat BE, et al. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum Mutat. 2005;25:18-21.
6. Urade Y, Ujihara M, Horiguchi Y, et al. The major source of endogenous prostaglandin D2 production is likely antigenpresenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol. 1989;143:2982-2989.
7. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006;70:1844-1849.
8. Tang Y, Zhou L, Gunnet JW, et al. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun. 2006;345:29-37.
9. Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res. 2004;43:3-35.
10. Morrow JD, Parsons WG 3rd, Roberts LJ 2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263-274.
11. Skosnik PD, Yao JK. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids. 2003;69:367-384.
12. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126:2637-2646.
13. Messamore E, Hoffman WF, Yao JK. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr Res. 2010;122:248-256.
14. Smesny S, Kinder D, Willhardt I, et al. Increased calciumindependent phospholipase A2 activity in first but not in multiepisode chronic schizophrenia. Biol Psychiatry. 2005;57:399-405.
15. Tavares H, Yacubian J, Talib LL, et al. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res. 2003;61:1-6.
16. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2003;69:413-419.
17. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis. 4th ed. Upper Saddle River, New Jersey: Prentice Hall; 1998:22-23.
18. Henze N, Zirckler B. A class of invariant consistent tests for multivariate normality. Commun Statist - Theory Meth. 1990;19:3595-3617.
19. Garver DL, Holcomb JA, Christensen JD. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry. 2000;61:964-72.
20. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
21. Ross BM, Hughes B, Turenne S, et al. Reduced vasodilatory response to methyl-nicotinate in schizophrenia as assessed by laser doppler flowmetry. Eur Neuropsychopharma. 2004;14:191-197.
22. Chang SS, Liu CM, Lin SH, et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: The effect of genetic loading. Schizophr Bull. 2009;35:213-221.
23. Lin SH, Liu CM, Chang SS, et al. Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives. Schizophr Bull. 2007;33:174-182.
24. Maclean R, Ward PE, Glen I, et al. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:927-933.
25. Hudson CJ, Lin A, Cogan S, et al. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia. Biol Psychiatry. 1997;41:507-513.
26. Shah SH, Vankar GK, Peet M, et al. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr Res. 2000;43:163-164.
27. Winkelmann RK, Wilhelmj CM, Horner FA. Experimental studies on dermographism. Arch Dermatol. 1965;92:436-442.
28. Wilkin JK, Fortner G, Reinhardt LA, et al. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther. 1985;38:273-277.
29. Glen AI, Cooper SJ, Rybakowski J, et al. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids. 1996;55:9-15.
30. Lin A, Hudson CJ. The niacin challenge test in schizophrenia: past, present and future. Prostaglandins Leukot Essent Fatty Acids. 1996;55:17-19.
31. Puri BK, Richardson AJ, Counsell SJ, et al. Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: A (31)P magnetic resonance spectroscopy study. Prostaglandins Leukot Essent Fatty Acids. 2007;77:97-99.
32. Messamore E. Niacin subsensitivity is associated with functional impairment in schizophrenia. Schizophr Res. 2012;137:180-184.
33. Smesny S, Klemm S, Stockebrand M, et al. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2007;77:79-85.
34. Covault J, Pettinati H, Moak D, et al. Association of a long chain fatty acid-CoA ligase 4 gene polymorphismwith depression and with enhanced niacin-induced dermal erythema. Am. J. Med. Genet. Part B. 2004;127:42-47.
35. Lien YJ, Huang SS, Liu CM, et al. A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia. Schizophr Bull. 2013;39:68-76.
36. Hudson C, Gotowiec A, Seeman M, et al. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biol Psychiatry. 1999;46:401-405.